BCM
NVAX icon

Bluefin Capital Management’s Novavax NVAX Stock Holding History

Bluefin Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,500
Closed -$14K – 911
2020
Q4 		$14K Buy
+13,500
New +$1.43M ﹤0.01% 608

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bluefin Capital Management's NVAX Position: Q2 2021 in Review

Bluefin Capital Management sold out of Novavax (NVAX) in Q2 2021, closing a stake of 1,750 shares — an estimated $317K sold.

Bluefin Capital Management first reported a position in NVAX in Q3 2015 and held it in 3 quarters. The position peaked at $606K in Q4 2020. 408 funds tracked by Wall St. Rank hold NVAX as of Q2 2021.

  • Bluefin Capital Management reported no remaining Novavax position as of Q2 2021 after selling out during the quarter.
  • Bluefin Capital Management sold 1,750 Novavax shares in Q2 2021, an estimated $317K.
  • Bluefin Capital Management first reported a position in Novavax in Q3 2015 and held it in 3 quarters.
  • Bluefin Capital Management's Novavax position peaked at $606K in Q4 2020.
  • 408 funds tracked by Wall St. Rank held Novavax as of Q2 2021.

Based on Bluefin Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.